Grant: Canada Postdoctoral Research Award (CPRA) program
University of Calgary
$140,000.00
Defining the extracellular matrix proteome in multiple sclerosis: fibroblast-derived lumican as a novel player
FY 2025-26
Summary
In multiple sclerosis (MS), brain cells called oligodendrocytes, which make the insulating myelin sheaths around nerve fibers, are lost. Without this protection, nerve fibers gradually degenerate, leading to worsening disability over time. The brain does attempt to repair itself by making new myelin, a process called remyelination. Unfortunately, as MS advances, remyelination becomes less and less efficient.
Remyelination has clear benefits, including the potential to restore lost function. For this reason, boosting remyelination in people with MS is a major goal of research. However, scientists have discovered that certain factors within MS lesions actively block repair. Among the most important of these are scar-forming substances known as extracellular matrix (ECM) molecules. While over 300 ECM molecules are known in the human body, only about 10 have been examined in MS.
We have recently applied a novel technique that allows us to extract scar-associated molecules from MS lesions. This has enabled us to map, for the first time, the full spectrum of ECM molecules present in MS plaques. From this in-depth analysis, we have identified a previously unstudied ECM molecule called lumican, which our early experiments suggest is a potent inhibitor of remyelination.
In this project, we aim to understand exactly how lumican disrupts repair in MS. We will also test potential drugs that could prevent lumican from accumulating in lesions. Ultimately, our research will inform the development of therapies designed to overcome the inhibitory environment of MS lesions and promote functional recovery.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
536816
Name
Gorter Rianne P
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Defining the extracellular matrix proteome in multiple sclerosis: fibroblast-derived lumican as a novel player
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Extracellular Matrix; Lumican; Multiple Sclerosis; Remyelination Failure
Abstract
In multiple sclerosis (MS), brain cells called oligodendrocytes, which make the insulating myelin sheaths around nerve fibers, are lost. Without this protection, nerve fibers gradually degenerate, leading to worsening disability over time. The brain does attempt to repair itself by making new myelin, a process called remyelination. Unfortunately, as MS advances, remyelination becomes less and less efficient.
Remyelination has clear benefits, including the potential to restore lost function. For this reason, boosting remyelination in people with MS is a major goal of research. However, scientists have discovered that certain factors within MS lesions actively block repair. Among the most important of these are scar-forming substances known as extracellular matrix (ECM) molecules. While over 300 ECM molecules are known in the human body, only about 10 have been examined in MS.
We have recently applied a novel technique that allows us to extract scar-associated molecules from MS lesions. This has enabled us to map, for the first time, the full spectrum of ECM molecules present in MS plaques. From this in-depth analysis, we have identified a previously unstudied ECM molecule called lumican, which our early experiments suggest is a potent inhibitor of remyelination.
In this project, we aim to understand exactly how lumican disrupts repair in MS. We will also test potential drugs that could prevent lumican from accumulating in lesions. Ultimately, our research will inform the development of therapies designed to overcome the inhibitory environment of MS lesions and promote functional recovery.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Gorter, Rianne P
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~